Kangfang bioPD-1/CTLA-4 dual anti-treatment of hepatocellular carcinoma adaptation was approved clinically

On January 7, the CDE clinical trial publicity platform showed that Kangfang BioPD-1/CTLA-4 dual anti-treatment of hepatocellular carcinoma has been approved by default clinically.
AK104 is a new, potential next-generation pioneer PD-1/CTLA-4 dual-specific tumor immunotherapy drug developed by Kangfang Bio using Kangfang's unique Tetrabody dual-resistance platform, with the aim of achieving priority binding to tumor-soaked lymphocytes (TIL) rather than normal exoskeular tissue lymphocytes.
is a new attempt and breakthrough in the field of tumor immunotherapy, and is expected to become a new generation of tumor immunotherapy drugs better than PD-1 antibodies.
October 9, 2020, AK104 was recognized as cDE breakthrough therapy for the treatment of relapsed or metastatic cervical squamous cancer (including adenocarcinoma) adaptations that have been used to treat progressies in diseases that have been developed during or after platinum-containing therapy.
by Kangfang Bio's official website, Kangfang Bio has now established more than 30 antibody new drugs product line.
involved in PD-1, CD47, CD73, TIGIT, IL12/23, IL17, IL4R and other popular targets, of which 10 varieties are in the domestic and international clinical trial stage.